
How the Glucose Monitor Became a MAHA Fixation
To hear some of them tell it, the companies selling continuous glucose monitors have stumbled upon a heretofore unknown quirk of human biology. Seemingly healthy people, many of these companies argue, have 'glucose imbalances' that need to be monitored and, with dietary vigilance, eradicated. Millions of people are going through life eating bananas, not knowing that their blood sugar is rising with every bite. This must be stopped.
To this end, the companies market the continuous glucose monitor, or CGM, a quarter-size sensor that takes a near-constant measure of the glucose in the fluid between a person's cells. Once inserted into an arm, the sensor allows the wearer to monitor their blood-sugar levels on a phone app for $80 to $184 a month. Doing so allows you to 'see the impact of what you eat' (according to the start-up Lingo), to 'motivate behavior change and encourage healthier choices' (according to another called Levels), and to 'personalize your approach' to weight loss, because 'everyone's journey is different' (according to Nutrisense).
The gadgets have been revolutionary for many people with diabetes—previously the main available device for measuring blood sugar required users to prick their fingers multiple times a day. Many insurers cover CGM prescriptions for diabetics; they can pick up the devices at the pharmacy just as they would blood-test strips. But when I asked a half dozen experts whether people who don't have diabetes should wear CGMs, I got a resounding 'Meh.' 'It's a free country. People can pay money for whatever they feel like doing,' David Nathan, a diabetes expert at Harvard, told me. 'But from a medical point of view, I am personally unconvinced that they lead to any health benefit.'
Relying on a Harvard diabetes expert to give you diabetes advice, however, goes against the general ethos of the 'Make America Healthy Again' movement, many of whose members have been heavily promoting CGMs in recent months, including to people who don't have diabetes. Robert F. Kennedy Jr., the secretary of Health and Human Services, talked them up in an April CBS interview as 'extraordinarily effective in helping people lose weight and avoid diabetes.' At his Senate confirmation hearing, before becoming Food and Drug Administration commissioner, Marty Makary said glucose monitors help people 'learn about what they're eating.' Casey Means, the wellness influencer whom President Donald Trump nominated for surgeon general, has said that more Americans should use CGMs too. (As it happens, she is a co-founder of Levels.) 'I believe CGM is the most powerful technology for generating the data and awareness to rectify our Bad Energy crisis in the Western world,' Means wrote in her best-selling book, Good Energy. (Bad Energy is her term for the metabolic dysfunction that she believes to be at the root of many chronic health problems.)
The devices are emblematic of the self-reliance that characterizes the MAHA movement. 'The Casey Means's of the world,' Alan Levinovitz, a James Madison University religion professor who has studied alternative health, told me in an email, 'are using the rhetoric of naturalness as a way of telling people they can have complete control and expertise over their own health—which is the natural way to be healthy, rather than outsourcing that wisdom to top-down elites.' Indeed, one of the chapters of Good Energy is titled 'Trust Yourself, Not Your Doctor.' (Means did not respond to a request for comment.)
CGMs appear to have trickled into MAHA world from the Joe Roganosphere, helped along by the fact that the devices, which in the past had been prescribed mainly to diabetics, were made available last year for purchase over the counter—that is, by anyone. Five years ago, Paul Saladino, a doctor who promotes an ' animal-based diet,' said on Rogan's podcast, 'This is the kind of stuff that really tells you about your metabolic health. There's no way to lie with a continuous glucose monitor.' Since then, CGMs have been endorsed on popular wellness podcasts such as Andrew Huberman's Huberman Lab and Dave Asprey's The Human Upgrade, and by pop-health doctors such as Peter Attia and Mark Hyman, the latter of whom called the CGM 'a gadget that has completely changed my life.' A wellness influencer known as the Glucose Goddess said that although they may not be for everyone, CGMs can be 'a pretty incredible tool to start to connect what you're eating with what's actually happening inside of your body,' and offers a guide to them on her website. Gwyneth Paltrow, the empress of Goop, was recently spotted wearing one.
Sun Kim, a Stanford endocrinologist, told me that a few years ago, 'I was literally contacted by a start-up almost every month who wanted to incorporate a CGM' into their products. Of course, some CGM companies do specialize in people who have diabetes and need around-the-clock monitoring. But Kim and others I spoke with told me they suspect that, to boost sales, CGM manufacturers are trying to expand their potential-customer base beyond people living with diabetes to the merely sugar-curious.
Jake Leach, the president of Dexcom, maker of the over-the-counter CGM Stelo, told me via email, 'Stelo was originally designed for people who have Type 2 diabetes not using insulin and those with prediabetes, however, given the broad accessibility of this device, we are encouraged to see people without diabetes interested in learning more about their glucose and metabolic health.' A spokesperson for Dexcom pointed out to me that most people with prediabetes are undiagnosed. Fred St. Goar, a cardiologist and clinical adviser for Lingo, told me in a statement that CGMs can be beneficial for nondiabetics because 'understanding your body's glucose is key to managing your metabolism, so you can live healthier and better.'
Scant research exists on how many nondiabetic people are buying CGMs, but anecdotally, some providers told me that they are seeing an uptick. Nicola Guess, a University of Oxford dietician and researcher, said that '10 years ago, no, I never saw anyone without diabetes with a CGM. And now I see lots.' Mostly, she said, they're people who are already pretty healthy. In this sense, CGMs are an extension of the wearables craze: Once you have an Oura Ring and a fitness tracker, measuring your blood sugar can feel like the next logical step of the 'journey.'
Should people who aren't diabetic wear one of these? Health fanatics who have $80 a month to burn and want to see how various foods affect their blood sugar are probably fine to wear a CGM, at least for a little while. Spoiler: The readout is probably just going to show that eating refined carbs—such as white bread, pasta, and sweets—at least temporarily raises blood sugar to some degree.
Normal glucose patterns for nondiabetic people tend to vary quite a bit from meal to meal and day to day. Most nondiabetics' blood-sugar readings will typically fall within the 'normal' range of 70 to 140 milligrams per deciliter. But many healthy people will occasionally see spikes above 140, and scientists don't really know if that's a cause for concern. ('Great question' is a response I heard a lot when I asked.) In the studies he's worked on, Kevin D. Hall, a former National Institutes of Health nutrition scientist, has found that even in tightly controlled settings, people's blood-sugar levels respond very differently to the same meal when eaten on different occasions. Given all these natural deviations, a CGM may not be able to tell you anything especially useful about your health. And CGMs can be less accurate than other types of blood-sugar tests. In another study, Hall and his co-authors stuck two different brands of CGM on the same person, and at times, they provided two different blood-sugar readings. The conclusion, to Hall, was that more research is needed before CGMs can be recommended to nondiabetics.
What's more, blood sugar depends on sleep, stress, and exercise levels, and whether any given meal includes protein or fat. If you notice a spike after eating a banana, the banana might not be the reason. It might be the four hours of sleep you got the previous night, because sleep deprivation can affect the hormones that influence blood sugar. As a result, Guess said, 'a CGM cannot tell you whether a single food is right for you'—though some CGM enthusiasts make this promise. (A CGM can help you 'learn your reaction to individual foods and meals,' Means has written.)
For some people, tracking data does help nudge them toward healthier behaviors. If you get a clear readout from a CGM that your blood sugar has risen after you've eaten refined carbs, and it moves you to eat fewer refined carbs, that's not necessarily a bad thing. But researchers haven't found evidence yet that nondiabetic people eat better after wearing a CGM. And if you know how to read a CGM, you probably already know what a healthy diet looks like. You could just eat it. Anne Peters, a diabetes researcher at the University of Southern California, told me, 'You could just not wear it at all and tell yourself to eat more vegetables and a more plant-based diet and eat healthy, lean protein.'
Many of the biohackers who talk up CGMs also promote a low-carb, protein-heavy diet that would include a T-bone more readily than a Triscuit. (Asprey, the man behind The Human Upgrade, recommends putting butter in coffee.) The potential downside of glucose monitoring is that people who are (perhaps needlessly) alarmed by their CGM data will swap out healthy carbs such as fruit and whole grains for foods that are less healthy—butter, for example, or bacon and red meat. Those foods don't make an impact on blood sugar, but they can affect other markers of health, such as cholesterol and body fat. Eat a stick of butter, and your CGM will probably show a flat, pleasant line. But your arteries may protest.
I noticed these perverse incentives myself during my pregnancy, when I had gestational diabetes and wore a CGM to manage my blood sugar. A bowl of heart-healthy oatmeal would cause my blood-sugar reading to soar to an unacceptable 157, but a piece of cheesecake—with loads of fat balancing out the sugar—would keep it safely under my goal level of 135. At the time, I wanted to eat whatever kept my blood sugar low, for the sake of my baby. But few dieticians would advise healthy people to eat cheesecake instead of oatmeal every morning.
Glucose, after all, is just a small part of the picture of human health. 'Waist circumference, blood pressure, LDL cholesterol, resting heart rate—they are much better measures of how healthy someone is than glucose,' Guess said. And watching a real-time readout of your blood glucose can become an obsession of sorts—not an entirely harmless one. 'Something being a waste of time is a net harm,' Guess told me. 'There is something unethical to me about filling people's heads with worries that never come to pass.'
Many of the researchers I spoke with said that if you are concerned you might have diabetes or prediabetes, you could just get an A1c blood test at your annual physical. Like a CGM, it, too, measures blood sugar, but much more cheaply and without requiring you to wear a device all the time. And if it shows that you're at risk of developing type 2 diabetes, you could do what doctors have suggested doing for decades now: Eat a diet rich in vegetables and lean proteins, and get some exercise most days. ('Duh,' Nathan said.)
One way for Kennedy and others in the Trump administration to find out if CGMs do all they say they do would be to fund studies on whether CGMs are helpful, and for whom. Quite the opposite is happening. Hall recently left Trump's NIH because he believed he was being censored when speaking about the results of studies that conflicted with Kennedy's views, and Nathan's diabetes-prevention study was recently frozen by the Trump administration. So far, the administration has ended or delayed nearly 2,500 NIH grants, including some related to researching blood glucose. If the Kennedy-led HHS department truly would like to make America healthy again, it could stop defunding the people studying Americans' health.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Hill
2 hours ago
- The Hill
Carville: RFK Jr. ‘is going to kill more people than any Cabinet secretary, maybe in history'
Longtime Democratic strategist James Carville criticized Health and Human Services (HHS) Secretary Robert F. Kennedy Jr.'s vaccine approach, warning the secretary's policies could have fatal consequences for the country. 'Bobby Kennedy is going to kill more people than any Cabinet secretary, maybe in history, with his idiotic vaccine policy,' Carville said Wednesday in an interview on Fox News Channel's 'The Will Cain Show.' Carville added that vaccines are 'the greatest public health intervention in the history of the world,' and blasted Kennedy for what he characterized as sowing distrust in vaccines. 'He has expressed vaccine skepticism at every point,' Carville said. 'Every notable public health person thinks that vaccines are the greatest public health innovation in the history of the world.' 'What he's doing is going to kill people' Carville said of Kennedy. Kennedy has faced criticism for his recent decision to fire all 17 experts on the U.S. Centers for Disease Control and Prevention's (CDC) vaccine panel and replace them with eight of his own picks. The move marked a significant downsizing for the independent, expert panel that provides guidance on vaccine recommendations. Some new advisers have been accused of spreading misinformation about vaccines, but Kennedy has lauded the new team as capable. 'The slate includes highly credentialed scientists, leading public-health experts, and some of America's most accomplished physicians. All of these individuals are committed to evidence-based medicine, gold-standard science, and common sense,' he wrote in a post on X. The new members are set to meet June 25 to review safety and efficacy data for the current immunization schedule. The Hill has reached out to HHS for comment.


American Military News
4 hours ago
- American Military News
RFK Jr. plans crackdown on pharma ads in threat to $10 billion market
The Trump administration is discussing policies that would make it harder and more expensive for pharmaceutical companies to advertise directly to patients, in a move that could disrupt more than $10 billion in annual ad spending. Although the U.S. is the only place, besides New Zealand, where pharma companies can directly advertise, banning pharma ads outright could make the administration vulnerable to lawsuits, so it's instead focusing on cutting down on the practice by adding legal and financial hurdles, according to people familiar with the plans who weren't authorized to speak publicly on the matter. The two policies the administration has focused in on would be to require greater disclosures of side effects of a drug within each ad — likely making broadcast ads much longer and prohibitively expensive — or removing the industry's ability to deduct direct-to-consumer advertising as a business expense for tax purposes, these people said. The discussions are ongoing and plans could still change before the agency undertakes any action, they said. Limiting pharma ads would be a major win for Health and Human Services Secretary Robert F. Kennedy Jr. He's long wanted to more strictly regulate how medicines are promoted. He's said he believes Americans consume more drugs than people in other countries because of the U.S. drug companies' ability to directly advertise to consumers. The new policies could threaten a key source of revenue to advertising and media companies, as well as the U.S. pharmaceutical industry. Companies spent $10.8 billion in 2024 on direct-to-consumer pharmaceutical advertising in total, according to a report from the advertising data firm MediaRadar. AbbVie Inc. and Pfizer Inc. were particularly big spenders. AbbVie alone spent $2 billion on direct-to-consumer drug ads last year, primarily on advertising for the company's anti-inflammatory drugs Skyrizi and Rinvoq. The medicines brought in more than $5 billion for AbbVie in the first quarter of 2025. 'We are exploring ways to restore more rigorous oversight and improve the quality of information presented to American consumers,' HHS spokesperson Andrew Nixon said in a written statement, adding that no final decisions have been made. AbbVie shares fell as much as 2.3% on Tuesday, their biggest drop in a month. Pfizer shares slipped as much as 1.7%. Ad reversal Before the loosening of advertising regulations by the Food and Drug Administration in 1997, U.S. pharma companies had to list all possible side effects for a medication if they wanted to mention which condition the drug being advertised was intended to treat. Reading out a list of side effects took so long it drove up the cost for air time and meant there wasn't as much broadcast advertising as there is today, said Jim Potter, executive director of the Coalition for Healthcare Communication, a trade association. The FDA change allowed ads to disclose fewer side effects and also allowed companies to direct customers to talk to their doctors, call a telephone number, or visit a website to get more information on the advertised drugs. In the following years, TV pharma ad spending surged. In 2024, 59% of the pharmaceutical industry's spend was on television advertising, making pharma the third-highest spending industry on television ads, according to MediaRadar. If the Trump administration brings back some of those restrictions, broadcast ads may become more 'impractical,' according to Meredith Rosenthal, a professor of health economics and policy at Harvard University's school of public health, who has studied the impacts of pharma advertising. More specific drug ads could have benefits for patients who might be prompted to talk to their doctor for the first time about a medical condition like depression or erectile dysfunction, Rosenthal said. However, there are also drawbacks. Drug ads can be used to drive sales of expensive, brand-name medicines when lower-cost generic alternatives may be appropriate, she said. When asked if a crackdown on ads would hurt its business, AbbVie chief commercial officer Jeff Stewart told analysts at a conference in May that the company 'would have to pivot.' He said the company could shift its investment to 'disease awareness' or through advertising on digital channels rather than through mass media. Tax changes The Trump administration could also work with Congress to prohibit pharmaceutical companies from deducting direct-to-consumer advertising costs as business expenses on their taxes. House lawmakers discussed the idea in talks over President Donald Trump's tax cut legislation, but ultimately left the measure out of the bill. The Senate omitted it as well. HHS has been supportive of those discussions, according to a person familiar with the talks. Kennedy has also said publicly he's having conversations about tax changes within the administration, telling Senator Josh Hawley during a May hearing on Capitol Hill that he expected an announcement on the matter 'within the next few weeks.' Joe Grogan, who served as White House Domestic Policy Council chief during President Donald Trump's first term and now consults for health-care companies, said it's unclear whether lawmakers will have an appetite to crack down on the pharmaceutical industry further given Trump's tariff threats and demands to dramatically lower drug prices. Meanwhile, the pharmaceutical industry has warned that allowing lawmakers to regulate advertising by changing the tax code to single out pharmaceutical companies could set a dangerous precedent and raise the specter of lawsuits. Other industries also can deduct advertising costs as business expenses, heightening concerns they could be targeted next. 'If you choose a sector, if one becomes a target, everyone becomes a target,' said Potter of the Coalition for Healthcare Communication. The National Association of Broadcasters, which represents companies that own radio and television stations, said the group opposes restrictions on direct-to-consumer advertising, and that revenue from ads allows local broadcasters to staff newsrooms and invest in weather technology. 'Restricting pharmaceutical ads would have serious consequences for stations, particularly those in smaller markets, and could raise First Amendment concerns,' NAB spokesperson Alex Siciliano said. ___ © 2025 Bloomberg L.P. Distributed by Tribune Content Agency, LLC.


The Hill
5 hours ago
- The Hill
Children will get sick and die because Trump owed RFK Jr. a favor
Is it a political mistake to kill your voters and their children? That hypothesis will soon be tested. Secretary of Health and Human Services Robert F. Kennedy Jr.'s recent mass firing of the CDC's Advisory Committee on Immunization Practices is only the latest step in his years-long campaign against vaccination. In the face of a measles outbreak in Texas, he spread misinformation and trumpeted quack remedies. He has canceled vaccine development, cut off research into vaccine hesitancy and joined Elon Musk in massively cutting his agency's budget and staff. Kennedy has this power because his support helped elect Trump, and this is his reward. Democrats ought to hold the Trump administration accountable. Before that can happen, though, the public needs to understand the danger. Here are the facts about measles, the most contagious of the diseases that Kennedy threatens to bring back to America. You can get it by entering a room where an infected person was two hours earlier. It causes long-term damage to the immune system, leaving children at risk of illness from other diseases for years. About one child out of every 1,000 who get measles will develop encephalitis (swelling of the brain). This can lead to convulsions and leave the child deaf or with an intellectual disability. Between one and three of every 1,000 children who become infected will die from respiratory and neurologic complications. Unvaccinated people pose a constant threat, since infants cannot be immunized until they are a year old. In Germany in 2000, an unvaccinated 11-year-old boy was taken to the pediatrician with a fever. He had measles and infected six children in the waiting room, including three babies. Two of them developed an incurable complication that usually appears years after the victim seems to have recovered. It produces first cognitive impairment and behavioral problems, then seizures, and finally slow deterioration and death. That is what happened to those two infants. One study found that, for babies who get measles before being vaccinated, the rate of this complication is one in 609. Try scaling that up to the U.S. population. Kennedy has promoted the myth, since debunked, that the measles vaccine causes autism. He once stated, 'Measles outbreaks have been fabricated to create fear that in turn forces government officials to 'do something.' They then inflict unnecessary and risky vaccines on millions of children for the sole purpose of fattening industry profits.' He has also said, 'I'm a freedom-of-choice person' about vaccines. But if his newly reconstituted committee removes vaccines from the schedules, families will lose insurance coverage for vaccination and may not be able to choose to vaccinate. The freedom he is talking about is the freedom to kill children, one's own and other people's. Kennedy's replacements for the CDC's experts are unqualified, and a few of them are anti-vaccine cranks. He also has promoted the quack notion that measles can be treated with Vitamin A, and HHS even sent doses of the vitamin to Texas after an outbreak. People evidently believed him, and children in West Texas were hospitalized for Vitamin A overdoses. Elections are sometimes won by raising issues that had not been in the news but that voters can unexpectedly be convinced to care about. Democrats have an opportunity here. The worst thing the Trump administration has done — and it is an extremely competitive field — is the destruction of the U.S. Agency for International Development. Since the administration cut off food and medical aid to foreign countries, about 300,000 people have died, most of them children. Millions more are threatened — including some Americans, because when mpox and drug-resistant tuberculosis spreads uncontrolled elsewhere, it will eventually find its way here. Bill Gates responded by accelerating a $20 billion payout from his foundation to ameliorate the damage. That isn't enough to compensate for Trump's cuts, but it will save millions. Gates is a modern Oskar Schindler, rescuing people whom others are trying to kill. Gates could be a model for other philanthropists — and, perhaps, political donors. Part of what makes the anti-vaccine movement so dangerous is that it is so well-funded. Its organizations raise more than $20 million a year, which they use to aggressively spread their lies on social media. The same techniques could be deployed on behalf of the truth. But the largest organization that is trying, the Vaccine Integrity Project, has raised just $240,000. Once people understand the science, there could be political consequences. Even if there aren't, countering the misinformation would certainly save lives. Everybody should know the stories of Micha and Natalie, the two German children who were infected at the doctor's office. Natalie died in 2011 and Micha in 2013. There are videos that show them when they were healthy, and then later when they were paralyzed and wheelchair-bound. The videos are horrible to watch. Everyone should see them. They show what it will mean to live in the Trump administration's world full of unvaccinated people. Parents will helplessly watch their children sicken and die because Trump owed Kennedy a favor. Most people don't even know about SSPE. A social media campaign could change that. It would also put pressure on the Republican senators who voted to confirm Kennedy — all of them, except for polio survivor Sen. Mitch McConnell (R-Ky.) — to explain themselves. It might even help flip a Senate seat or two. Are any billionaires reading this? You could be a Schindler, too. Andrew Koppelman, the John Paul Stevens Professor of Law at Northwestern University, is the author of 'Burning Down the House: How Libertarian Philosophy Was Corrupted by Delusion and Greed.'